Micropump & TRIGGER LOCK Products Developed in Partnership

COREG CR™

Flamel licensed the worldwide rights for the application of Micropump® to GlaxoSmithKline (GSK) for a beta blocker used for the treatment of hypertension, heart failure and heart attack.

COREG CR is unique in that it permits once daily dosing for patients, with no increase in Cmax or Cmin. Click here to see the Coreg CR pharmacokinetic curve.

GSK announced on March 22, 2007 nationwide availability of once-a-day Coreg CR™ for the treatment of three key cardiovascular conditions

Results from the COMPARE trial were presented on September 22nd, 2008 at the Heart Failure Society of America (HFSA) Annual Meeting by Dr. Barry Greenberg, President of the HFSA.
The trial compared Coreg CR™ with Coreg immediate release in subjects with stable chronic heart failure (CHF).
The primary endpoint was the effect on left ventricular ejection fraction (non inferiority).
Secondary endpoints included changes in left ventricular remodeling, changes in brain natriuretic peptide levels (BNP), medication compliance and drug-dose tolerability, rate of hospitalization (heart failure and all other causes), and all-cause mortality.
All the endpoints of that study were met.

Trigger Lock™, application of MICROPUMP for pain management

Opioid analgesics are used to treat patient suffering from severe and chronic pain. A major problem faced by the industry is the growing abuse and misuse of its drugs by drug abusers, who extract the active ingredient from the drugs and achieve their immediate release. We have applied our MICROPUMP technology to address this issue in creating Trigger Lock.

Trigger Lock products cannot be crushed to extract the active ingredients. We believe that other methods commonly employed by drug abusers to liberate the active ingredient are also ineffective as against Trigger Lock.

Flamel is engaged in a feasibility program with a major pain therapy company to assess the applicability of Trigger Lock to multiple molecules.